TY - JOUR
T1 - Potential drug-drug interactions among hospitalised TB patients
AU - Thomas, L.
AU - Kurian, S. J.
AU - Mukherjee, N.
AU - Thomas, R. B.
AU - Keerthanaa, B.
AU - Sekhar, S. M.
AU - Subeesh, V.
AU - Banerjee, M.
AU - Varma, M.
AU - Rao, M.
N1 - Publisher Copyright:
© 2022 The Union.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - BACKGROUND: Hospitalised TB patients are at heightened risk for developing drug-drug interactions (DDIs) due to overlapping CYP450 enzyme and/or drug transporter biotransformation of anti-TB drugs and co-medications given for treating TB-associated comorbidities. We aimed to compare the occurrence, characterisation and determinants of database identified potential DDIs (pDDIs) associated with first-line anti-TB drugs and other co-medications using a subscription and free access drug information database.METHOD: This was a single-centre retrospective study to assess pDDIs between first-line anti-TB drugs and other medications for comorbidities among hospitalised TB patients using IBM Micromedex® and Drugs.com.RESULTS: On multivariate regression analysis, hospitalised TB patients with comorbidities such as diabetes mellitus, HIV infection and hypertension, longer hospitalisation, and patients administered with more than seven drugs during their hospital stay were associated with increased risk for the occurrence of pDDIs. Significant discrepancies were observed in the detection and severity of pDDIs between IBM Micromedex and Drugs.com.CONCLUSION: We recommend using free access drug information database to a subscription drug information database in drug interaction screening protocols in clinics for enhanced identification of pDDIs and reducing monetary burden in resource-limited settings.
AB - BACKGROUND: Hospitalised TB patients are at heightened risk for developing drug-drug interactions (DDIs) due to overlapping CYP450 enzyme and/or drug transporter biotransformation of anti-TB drugs and co-medications given for treating TB-associated comorbidities. We aimed to compare the occurrence, characterisation and determinants of database identified potential DDIs (pDDIs) associated with first-line anti-TB drugs and other co-medications using a subscription and free access drug information database.METHOD: This was a single-centre retrospective study to assess pDDIs between first-line anti-TB drugs and other medications for comorbidities among hospitalised TB patients using IBM Micromedex® and Drugs.com.RESULTS: On multivariate regression analysis, hospitalised TB patients with comorbidities such as diabetes mellitus, HIV infection and hypertension, longer hospitalisation, and patients administered with more than seven drugs during their hospital stay were associated with increased risk for the occurrence of pDDIs. Significant discrepancies were observed in the detection and severity of pDDIs between IBM Micromedex and Drugs.com.CONCLUSION: We recommend using free access drug information database to a subscription drug information database in drug interaction screening protocols in clinics for enhanced identification of pDDIs and reducing monetary burden in resource-limited settings.
UR - http://www.scopus.com/inward/record.url?scp=85143073089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143073089&partnerID=8YFLogxK
U2 - 10.5588/ijtld.22.0107
DO - 10.5588/ijtld.22.0107
M3 - Article
C2 - 36447328
AN - SCOPUS:85143073089
SN - 1027-3719
VL - 26
SP - 1137
EP - 1143
JO - The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
JF - The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
IS - 12
ER -
